Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men. The average age of a prostate cancer diagnosis is 66 years.
The Prostate Cancer market is anticipated to reach a value of USD XX billion by 2026.
Market Drivers:
Increasing disease prevalence will act as the primary driver for market growth. An increasing trend is to bring effective immune-based cancer treatments to patients with prostate cancer. Immunotherapy is a promising new treatment currently being developed in research. Provence, also known as sipuleucel-T is the only FDA-approved immunotherapy for prostate cancer.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
